Is QuidelOrtho’s (QDEL) Distress-Zone Z-Score Overshadowing Its Core Diagnostics Story?

Simply Wall St.01-26

In recent days, QuidelOrtho has faced renewed scrutiny over its financial position, with analyses pointing to negative earnings, shrinking margins, a low interest coverage ratio and an Altman Z-Score ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606647182?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401","is_english":true,"pubTime":"2026-01-26 06:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606647182","market":"nz","top_or_hot":-1,"title":"Is QuidelOrtho’s (QDEL) Distress-Zone Z-Score Overshadowing Its Core Diagnostics Story?","media":"Simply Wall St.","content":"<div>\n<p>In recent days, QuidelOrtho has faced renewed scrutiny over its financial position, with analyses pointing to negative earnings, shrinking margins, a low interest coverage ratio and an Altman Z-Score ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/is-quidelorthos-qdel-distress-zone-z-score-overshadowing-its\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is QuidelOrtho’s (QDEL) Distress-Zone Z-Score Overshadowing Its Core Diagnostics Story?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs QuidelOrtho’s (QDEL) Distress-Zone Z-Score Overshadowing Its Core Diagnostics Story?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-26 06:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/is-quidelorthos-qdel-distress-zone-z-score-overshadowing-its><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In recent days, QuidelOrtho has faced renewed scrutiny over its financial position, with analyses pointing to negative earnings, shrinking margins, a low interest coverage ratio and an Altman Z-Score ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/is-quidelorthos-qdel-distress-zone-z-score-overshadowing-its\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/is-quidelorthos-qdel-distress-zone-z-score-overshadowing-its","article_id":"2606647182","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-qdel/quidelortho/news/is-quidelorthos-qdel-distress-zone-z-score-overshadowing-its","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2606647182","pubTimestamp":1769379063,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In recent days, QuidelOrtho has faced renewed scrutiny over its financial position, with analyses pointing to negative earnings, shrinking margins, a low interest coverage ratio and an Altman Z-Score of 0.2 that places the diagnostics group in the distress zone.\nAlongside these concerns, the company has highlighted its role in blood-supply resilience and plans to report fourth-quarter and full-year 2025 results on February 11, 2026, underscoring a contrast between operational initiatives and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","BK4082":"医疗保健设备","QDEL":"窥得儿医药"},"translate_title":"QuidelOrtho(QDEL)的困境区域Z分数是否掩盖了其核心诊断故事？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QDEL":1.5},"content_text":"In recent days, QuidelOrtho has faced renewed scrutiny over its financial position, with analyses pointing to negative earnings, shrinking margins, a low interest coverage ratio and an Altman Z-Score of 0.2 that places the diagnostics group in the distress zone. Alongside these concerns, the company has highlighted its role in blood-supply resilience and plans to report fourth-quarter and full-year 2025 results on February 11, 2026, underscoring a contrast between operational initiatives and balance sheet pressure. Against this backdrop, we will examine how mounting worries about QuidelOrtho’s financial health shape the company’s investment narrative in the near term. AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementWhat Is QuidelOrtho's Investment Narrative?For anyone considering QuidelOrtho, the big picture you need to buy into is that a business with deep roots in in vitro diagnostics and blood-supply infrastructure can work through heavy losses and a tight balance sheet to make its portfolio count. The recent share price drop, renewed focus on the Altman Z-Score of 0.2 and concerns about interest coverage have pushed financial risk, not product news, to the foreground. At the same time, the Science Bytes episode on blood-supply pressures and automation, plus ongoing product clearances like the VITROS hs Troponin I assay, reinforce that QuidelOrtho still sits in clinically important workflows. The upcoming February 11 results now look like an even sharper near term catalyst: they are where investors will look for signs of cash preservation, margin repair and whether operational momentum can realistically offset distress indicators. However, the company’s short cash runway and continued losses are information investors should not overlook.\n\nDespite retreating, QuidelOrtho's shares might still be trading above their fair value and there could be some more downside. Discover how much.Exploring Other PerspectivesQDEL 1-Year Stock Price Chart Three Simply Wall St Community fair value views cluster between about US$38 and US$84, underlining how far apart investors can be on QuidelOrtho. Set that against the recent price drop and distress-zone Altman Z-Score, and it is clear you are weighing balance sheet strain against a diagnostics platform that some still model as materially undervalued.Explore 3 other fair value estimates on QuidelOrtho - why the stock might be worth just $38.33!Build Your Own QuidelOrtho NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your QuidelOrtho research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.Our free QuidelOrtho research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate QuidelOrtho's overall financial health at a glance.Contemplating Other Strategies?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:Find companies with promising cash flow potential yet trading below their fair value.Uncover the next big thing with financially sound penny stocks that balance risk and reward.The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if QuidelOrtho might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606647182","isCrawlerRequest":true}